The humpback whale raised out of the water just feet from the boat, rolling and spy hopping for its fans. Americans are ...

Americans are running out of time to claim a $1,400 stimulus check. Tuesday marks Tax Day as well as the three-year deadline ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and ...

Amid the worst U.S.-China trade clash in modern history, Michelle Xia thinks she has something Chinese that Americans will ...

The U.S. is preparing to announce sweeping tariffs on pharmaceutical imports within the next two months, according to ...

Pharmac will fund a new type of insulin for people with diabetes, branded as Ryzodeg, from 1 May 2025. Pharmac’s Director Pharmaceuticals, Geraldine MacGibbon, expects about 13,000 people with ...

As we've just reported, Donald Trump has raised tariffs against China to 125%, and also issued a 90 day pause to some tariffs ...

Growth through acquisition has been an attractive option for many organizations in the pharma cold chain. One recent example ...

In the sleepy suburb of Bagsværd, a 25-minute train ride from Denmark’s capital of Copenhagen, weight-loss drugmaker Novo Nordisk is everywhere. Street after street is filled with the company ...

Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists ...

Novo Nordisk will pay as much as $2 billion for a new obesity drug called UBT251 The company now holds the exclusive rights to develop, manufacture and sell the drug in much of the world It has ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...